KUALA LUMPUR: ADT Biotech Sdn Bhd, the newly-launched Asia-Pacific headquarters of Germany-based Altona Diagnostic, eyes more market share in infectious disease testing in the region.
Its managing director, Dr Finn Zedler, said currently, the company held between 5% and 10% share in the diagnostics market.
“The company is quite small in the overall molecular diagnostics market, because we provide a very specialised product in a specialised area.
“Our expertise lies in the niche markets of emerging diseases such as tuberculosis as well as the tropical infectious diseases such as dengue,” he told Bernama after the launch of the headquarters here yesterday.
Zedler said the company was interested to work with research organisations, hospitals and laboratories in the country as well as in the region.
Meanwhile, Altona Diagnostics founder, Dr Ulrich Spengler, said the company currently offered over 35 products.
However, not all of them were relevant in the region, he said.
“It depends on the presence of these viruses and bacteria, as well as the local conditions and reimbursement structures here,” he said.
Spengler said the group, which already has a presence in Germany, was optimistic of the good opportunities here.
The company was driven to pick Malaysia as its regional hub due to its scientific achievements and the unique collaboration opportunities with local institutions in the country, he said.
“Furthermore, Malaysia has the skills, talent and infrastructure that we require, conducive business environment as well as a solid platform for our regional activities,” he said. - Bernama